Ascendis Pharma A/S (ASND) shares soared over 8% in pre-market trading on Thursday, propelled by a set of positive catalysts. The biopharmaceutical company reported better-than-expected fourth-quarter earnings after the market close on Wednesday, with a narrower-than-anticipated loss and revenue beat.
Ascendis' fourth-quarter loss of €0.64 per share came in lower than analysts' estimates of a €0.96 loss, while revenue of €173.92 million topped expectations of €119.71 million. The strong financial performance in Q4 capped off a solid fiscal 2024 for the company, marked by significant growth in revenue and improving profitability.
Additionally, Ascendis announced that its board has approved a $25 million share repurchase program, further fueling the stock's pre-market rally. The buyback plan includes the repurchase of up to $18.3 million worth of American depositary shares and a $9 million net settlement of certain restricted stock units. The buyback announcement, combined with the upbeat earnings report and a reiterated Buy rating from J.P. Morgan, helped drive investor enthusiasm for ASND shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.